Full Breakdown
Zimbabwe Launches Lenacapavir: A New Era in HIV Prevention
2/23/2026, 2:14:45 AM
Introduction of Lenacapavir in Zimbabwe
On Thursday, Zimbabwe became one of the first countries to introduce lenacapavir, a long-acting HIV prevention drug that requires administration only twice a year. The launch took place in Harare, where individuals, including young women and sex workers, lined up for injections. Health officials view lenacapavir as a potential turning point in the fight against HIV, particularly for high-risk groups. However, challenges such as funding constraints and infrastructure gaps may hinder its widespread impact.
Advantages of Lenacapavir
Lenacapavir offers significant advantages over traditional daily oral pre-exposure prophylaxis (PrEP), which has been available in Zimbabwe but often faced adherence issues due to stigma and lifestyle factors. Constance Mukoloka, a 27-year-old sex worker, expressed relief after receiving her injection, stating that the drug alleviates the stigma associated with visible medication, which often deterred clients. Zimbabwe's Health Minister Douglas Mombeshora emphasized that "prevention must fit into real life," highlighting lenacapavir's discreetness and extended duration as critical benefits for key populations.
Context of HIV in Zimbabwe
Zimbabwe, along with Eswatini and Zambia, has made significant strides in controlling the HIV epidemic, achieving World Health Organization targets for testing, treatment, and viral suppression. Despite these advancements, new infections remain a pressing concern, particularly among adolescent girls and young women, who account for a disproportionate share of new cases in sub-Saharan Africa. According to UNAIDS, women and girls represented 63% of new HIV infections in the region in 2024.
Rollout Plans and Challenges
The initial phase of lenacapavir's rollout in Zimbabwe aims to benefit approximately 46,000 individuals across 24 sites. However, the government faces financial constraints in expanding the program. While Gilead Sciences has committed to selling lenacapavir at no profit to low and middle-income countries, the high cost of mass rollouts remains a significant barrier. In Kenya, for instance, the negotiated price for the injectable is about $54 per person per year, which may still be unaffordable for many.
Criticism and Concerns
Health officials and activists caution that the practical realities of implementing lenacapavir could undermine its potential benefits. Bellinda Thibela from Health GAP noted that while reduced pricing is a positive step, it does not address the underlying issues of inadequate health infrastructure and diminishing external funding. Enerst Chikwati from the AIDS Healthcare Foundation stressed the continued importance of condoms as a cost-effective means of preventing HIV and other sexually transmitted infections.
Verbatim Quotes
- "I am safe, I can work with confidence now." — Constance Mukoloka, Sex Worker
- "Prevention must fit into real life." — Douglas Mombeshora, Zimbabwe Health Minister
- "What's the point of having a reduced price if there is no staff and equipment in clinics?" — Bellinda Thibela, Health GAP
- "I am elated. I can go for a whole six months feeling safe." — Constance Mukoloka, Sex Worker
The rollout of lenacapavir in Zimbabwe represents a significant advancement in HIV prevention, but its success will depend on overcoming financial and infrastructural challenges to ensure that this promising treatment reaches those who need it most.
